Previous Section Index Home Page

27 Feb 2006 : Column 405W—continued

HEALTH

Our Health, Our Care, Our Say"

Mr. Andy Reed: To ask the Secretary of State for Health which agency will be responsible for delivering the Fitter Britain campaign announced in Our Health, Our Care, Our Say: a new direction for community services"; and what funding will be committed to the campaign. [51129]

Caroline Flint: Over the coming year we will work with our partner organisations, including Sport England, the London Olympic Games organising committee and across Government, to maximise opportunities for people to take part in recreational health promoting activities. Part of this work will be to develop a campaign and agree the necessary resources that build on the health strategies for England, Scotland, Wales and Northern Ireland.

Your Health, Your Care, Your Say"

Sandra Gidley: To ask the Secretary of State for Health what new information was gained as a result of the consultation, Your Health, Your Care, Your Say". [51341]

Mr. Byrne: Your Health, Your Care, Your Say" was a wide-ranging listening exercise which unlike previous consultations gave members of the public an opportunity to debate various options for improving community health and social care services. The public's priorities for community health and social care are set
 
27 Feb 2006 : Column 406W
 
out in a research report which is available on the Department's website at: www.dh.gov.uk/assetRoot/04/12/74/64/04127464.pdf.

Advocacy Services

Steve Webb: To ask the Secretary of State for Health what steps she is taking to ensure that there will be an efficient handover of outstanding cases following the termination of the North East Independent Complaints Advocacy Services contract with the Citizens Advice Bureau. [45357]

Mr. Byrne: Citizens Advice is working closely with the new providers in order to ensure a smooth transition for clients. Detailed transition plans have been drawn up, the implementation of which will be monitored by departmental officials.

Agency Nurses

Mr. Spring: To ask the Secretary of State for Health what the cost of agency nurses was in NHS organisations in Suffolk in each year since 1997. [50692]

Ms Rosie Winterton: The following tables show the total expenditure on non-national health service employed nursing staff in NHS organisations by organisations in Suffolk:
Table 1. Expenditure by primary care trusts (PCTs) since 2002–03, when PCTs were formed.
£000

Organisation2004–052003–042002–03
Ipswich PCT172227
Suffolk Coastal PCT1171305
Central Suffolk PCT36100145
Suffolk West PCT795656
Waveney PCT166149202

Table 2: Expenditure by NHS trusts since 1997.
£000

Organisation2004–052003–042002–032001–022000–011999–20001998–991997–98
Ipswich Hospital NHS Trust1,1021,419898939726479377159
West Suffolk Hospitals NHS Trust401304878995328660503512
East Anglian Ambulance NHS Trust00000000
Suffolk Mental Health Partnership Trust725861000000




Note:
Expenditure is for non-NHS employed staff including nursing, midwifery and health visiting.
Source:
Annual financial returns of NHS trusts and PCTs.




Alzheimer's Disease

Joan Walley: To ask the Secretary of State for Health what meetings she has had with providers of dementia specialist services to discuss the potential impact of withdrawing anticholinisterase drug treatments for people in the early stages of Alzheimer's disease. [50140]

Mr. Byrne: Since the National Institute for Health and Clinical Excellence issued its latest appraisal consultation document on the use of Alzheimers drugs on 23 January, Ministers have met with representatives of the Alzheimers Society.

Joan Walley: To ask the Secretary of State for Health what estimate she has made of the number of people who care for people with Alzheimer's disease. [50203]

Mr. Byrne: The information requested is not held centrally.

Joan Walley: To ask the Secretary of State for Health if she will make a statement on the availability on the NHS of memantine for the treatment of moderately severe to severe Alzheimer's disease. [50204]

Mr. Byrne: Memantine is currently licensed for the treatment of moderately severe to severe Alzheimer's disease and as such can be prescribed by clinicians on the national health service. The National Institute for Health and Clinical Excellence (NICE) has recently consulted on draft guidance for the use of four drugs,
 
27 Feb 2006 : Column 407W
 
including memantine, in the treatment of Alzheimer's disease. I understand that NICE will be publishing its final guidance to the NHS later this year.

Joan Walley: To ask the Secretary of State for Health (1) what research has been evaluated on the impact of drug treatments for Alzheimer's disease on entry into full-time care; [50208]

(2) what assessment has been made of the potential impact of the restriction of drug treatments for Alzheimer's disease proposed by the National Institute for Health and Clinical Excellence on the requirement for (a) care services, (b) care homes and (c) carer time. [51087]

Mr. Byrne: The Department does not hold comprehensive information on research conducted into drug treatments for Alzheimers disease, but I understand that this issue has been addressed in published research

The National Institute for Health and Clinical Excellence's appraisal consultation document sets out in detail the issues that have been considered in arriving at its draft advice.

Joan Walley: To ask the Secretary of State for Health how many people were diagnosed with Alzheimer's disease in each of the last 10 years. [51088]

Mr. Byrne: The information on the number of people who were diagnosed with Alzheimer's disease in each of the last 10 years is shown in the table.

All diagnoses count of finished consultant episodes and patients with a diagnosis of Alzheimer's disease in national health service hospitals, England, 1995–96 to 2004–05.
Finished consultant episodesPatient count
1995–9627,411n/a
1996–9731,641n/a
1997–9830,36917,379
1998–9930,49317,776
1999–200028,60116,830
2000–0129,32916,666
2001–0232,04217,938
2002–0319,48535,369
2003–0438,87421,877
2004–0544,21324,214




Notes:
1. Finished consultant episode (FCE)
An FCE is defined as a period of admitted patient care under one consultant within one healthcare provider. Please note that the figures do not represent the number of patients, as a person may have more than one episode of care within the year.
2. All diagnoses count of episodes
These figures represent a count of all FCE's where the diagnosis was mentioned in any of the 14 (seven prior to 2002–03) diagnosis fields in a Hospital Episode Statistics (HES) record.
3. Diagnosis (primary diagnosis)
The primary diagnosis is the first of up to 14 (seven prior to 2002–03) diagnosis fields in the HES data set and provides the main reason why the patient was in hospital.
4. Secondary diagnoses
As well as the primary diagnosis, there are up to 13 (six prior to 2002–03) secondary diagnosis fields in Hospital Episode Statistics (HES) that show other diagnoses relevant to the episode of care.
5. Patient counts
Patient counts are based on the unique patient identifier HES identification (HESID). This identifier is derived based on patient's date of birth, postcode, sex, local patient identifier and NHS number, using an agreed algorithm. Where data are incomplete, HESID might erroneously link episodes or fail to recognise episodes for the same patient. Care is therefore needed, especially where duplicate records persist in the data. The patient count cannot be summed across a table where patients may have episodes in more than one cell.
6. Grossing (finished consultant episodes)
Figures are grossed for both coverage and missing/invalid clinical data, except for 2003–04 and 2004–05, which is not yet adjusted for shortfalls.
Source:
HES, NHS Health and Social Care Information Centre





 
27 Feb 2006 : Column 408W
 

Joan Walley: To ask the Secretary of State for Health how much the Government has spent on research into Alzheimer's disease and other associated dementias in each year from 2000 to 2004; and if she will make a statement. [51089]

Jane Kennedy: The main agency through which the Government supports medical and clinical research is the Medical Research Council (MRC). The MRC is an independent body funded by the Department of Trade and Industry via the Office of Science and Technology. MRC expenditure on research into dementia 1 in the years in question was as follows:
£ million
2000–018.2
2001–026.6
2002–036.6
2003–047.4
2004–05not yet available


(111) Including Alzheimer's disease, general dementia. AIDS related dementia, Pick's disease and Huntingtons



£ million
2000–014.7
2001–022.9
2002–031.6
2003–041.1
2004–050.6

Joan Walley: To ask the Secretary of State for Health what meetings she has had with health professionals to discuss the National Institute for Health and Clinical Excellence proposal on the use of (a) Reminyl, (b) Aricept and (c) Exelon for the treatment of Alzheimer's disease. [51090]

Mr. Byrne: Since the National Institute for Health and Clinical Excellence issued its latest appraisal consultation document on the use of Alzheimer's disease drugs, on 23 January, Ministers have met with representatives of the Faculty of Old Age Psychiatry of the Royal College of Psychiatrists.

Rosie Cooper: To ask the Secretary of State for Health how many people were diagnosed with Alzheimer's disease in West Lancashire in each of the last 10 years. [51109]


 
27 Feb 2006 : Column 409W
 

Mr. Byrne: The information requested is shown in the table.
All diagnoses count of finished consultant episodes and patients with a diagnosis of Alzheimer's disease in West Lancashire Primary Care Trust

Finished consultant episodesPatient counts
1995–9654n/a
1996–9751n/a
1997–984535
1998–998855
1999–20007452
2000–018454
2001–0210772
2002–0312175
2003–0416990
2004–0512680




Notes:
Finished consultant episode (FCE)
An FCE is defined as a period of admitted patient care under one consultant within one healthcare provider. Please note that the figures do not represent the number of patients, as a person may have more than one episode of care within the year.
All diagnoses count of episodes
These figures represent a count of all FCE's where the diagnosis was mentioned in any of the 14 (seven prior to 2002–03) diagnosis fields in a Hospital Episode Statistics (HES) record.
Diagnosis (primary diagnosis)
The primary diagnosis is the first of up to 14 (seven prior to 2002–03) diagnosis fields in the HES data set and provides the main reason why the patient was in hospital.
Secondary diagnoses
As well as the primary diagnosis, there are up to 13 (six prior to 2002–03) secondary diagnosis fields in HES that show other diagnoses relevant to the episode of care.
Patient counts are based on the unique patient identifier HES identification (HESID). This identifier is derived based on patient's date of birth, postcode, sex, local patient identifier and national health service number, using an agreed algorithm. Where data are incomplete, HESID might erroneously link episodes or fail to recognise episodes for the same patient. Care is therefore needed, especially where duplicate records persist in the data. The patient count cannot be summed across a table where patients may have episodes in more than one cell.
Ungrossed data
Figures have not been adjusted for shortfalls in data, that is the data to ungrossed.
Source:
Hospital Episode Statistics, NHS Health and Social Care Information Centre




Rosie Cooper: To ask the Secretary of State for Health what estimate she has made of the number of people who care for people with Alzheimer's disease in West Lancashire constituency. [51111]

Mr. Byrne: The information requested is not held centrally.

Richard Ottaway: To ask the Secretary of State for Health what discussions were held with patients groups as part of the current National Institute for Health and Clinical Excellence appraisal of Alzheimer's drugs. [51229]

Jane Kennedy: The National Institute for Health and Clinical Excellence (NICE) published, Appraisal Consultation Documents" in March 2005 and January 2006 inviting comments from a wide range of stakeholders, including patient groups. Details of consultees for the appraisals are available on NICE's website at www.NICE.org.uk
 
27 Feb 2006 : Column 410W
 

Richard Ottaway: To ask the Secretary of State for Health what estimate she has made of the potential savings to the NHS as a consequence of the recommendations of the National Institute for Health and Clinical Excellence on Alzheimer's drugs. [51230]

Jane Kennedy: The National Institute for Health and Clinical Excellence has not yet finalised its recommendations on these drugs.

Dr. Stoate: To ask the Secretary of State for Health what discussions she has held with the National Institute for Health and Clinical Excellence (NICE) on her Department's submission to NICE in March 2005 in relation to Alzheimer's disease drugs; and if she will make a statement. [51624]

Jane Kennedy: I have had no meetings with the National Institute for Health and Clinical Excellence (NICE) to discuss the Department's submission of March 2005 in response to NICE's Appraisal Consultation Document".

Dr. Stoate: To ask the Secretary of State for Health what preferred assumptions were built into the cost-effectiveness outcomes section of the appraisal of drugs to treat Alzheimer's disease by the National Institute for Health and Clinical Excellence; and if she will make a statement. [51688]

Jane Kennedy: The assumptions used in this appraisal are contained in the assessment report which is available on the National Institute for Health and Clinical Excellence's (NICE) website at: www.nice.org.uk.

The assessment committee's consideration of these assumptions is addressed in its draft guidance, which is also available on NICE's website.

Mr. Lansley: To ask the Secretary of State for Health what her most recent estimate is of the number of patients suffering from (a) mild Alzheimer's and (b) moderate Alzheimer's who are receiving (i) donepezil, (ii) rivastigmine and (iii) galantamine for the treatment of their condition. [51894]

Mr. Byrne: The information requested is not held centrally.

Mr. Lansley: To ask the Secretary of State for Health what recent discussions she has had with the National Institute for Health and Clinical Excellence on its appraisal of donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's; on what dates these discussions were held; what the content of these discussions was; and if she will make a statement. [51896]

Jane Kennedy: I refer the hon. Member to the reply I gave to the hon. Member for Romsey (Sandra Gidley) on 7 February 2006, Official Report, columns 1179–80W.

Joan Walley: To ask the Secretary of State for Health what assessment she has made of the likely impact of the National Institute for Health and Clinical Excellence's recommendations on use of drug treatments for Alzheimer's disease on those in the early stages of the disease. [52319]


 
27 Feb 2006 : Column 411W
 

Mr. Byrne: The National Institute for Health and Clinical Excellence (NICE) has not yet published its final guidance to the national health service following its routine review. Until NICE issues new guidance the original 2001 guidance on anti-dementia drugs remains in force.


Next Section Index Home Page